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occur in 2-3,000 colon cancer patients every 
year in Turkey. Cost of treatment of CRC is 
also high. The National Institutes of Health 
estimated that direct medical costs including 
inpatient and outpatient care, drugs, and de-
vices for colon cancer amounted to $14 bil-
lion for the USA [9].
Treatments for metastatic colon cancer are 
mainly palliative and aim to increase the du-
ration and the quality of the patient’s remai-
ning life [10]. For many years 5-fluoroura-
cil (5-FU) was the only active agent which 
was associated with 12 month survival in 
colorectal cancer [10-12]. Several new ac-
tive chemotherapy and monoclonal antibo-
dies have been approved and implemented 
into routine clinical practice. Irinotecan, a 
INTRODUCTION
Colon cancer was reported as the third most 
prevalent in the world with 940,000 new ca-
ses and 500,000 deaths each year [1,2]. It was 
reported that 142,570 men and women were 
diagnosed with colorectal cancer (CRC) and 
57,000 men and women died in 2010 in US 
[3,4]. In Japan, colorectal cancer is the third 
leading cause of cancer death with 40,000 
death per year [5,6]. In Turkey, incidence of 
cancer is 173,85 per 100,000, 7,1 % of whom 
are diagnosed to have developed colon can-
cer [7]. In addition to prevalence and great 
mortality numbers metastases will develop in 
30-40% of CRC patients [8]. This metasta-
sis rate can also cause mortality. In the light 
of these, it could be said that metastases will 
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ABSTRACT
OBJECTIVES: Colon cancer is the third most common in the top cancer incidence list in Europe. In Europe 212,000 pa-
tients die every year due to colon cancer. In Turkey 120,000-130,000 new cancer patients are diagnosed every year, 7.1% 
of whom are diagnosed to have developed colon cancer. Metastases will occur in up to 50% of the patients who are newly 
diagnosed. Survival appears to be further prolonged to more than 20 months with new pharmaceuticals; however, these 
new pharmaceuticals increase the total cost of care. The aim of this study is to estimate the cost implications of new colon 
cancer treatment options for Turkey.
METHODS: Gazi University Hospital treatment protocols for colon cancer treatment were used. Cost of FUFA (5 FU/LV), 
FOLFIRI, FOLFOX, bevacizumab/FUFA, bevacizumab/FOLFIRI, bevacizumab/FOLFOX, irinotecan and irinotecan/ce-
tixumab protocols were calculated. The cost of combination of protocols were calculated depending on a Markov analysis. 
The exchange rate was US$ 1 for TL 1.5.
RESULTS: Depending on the life expectancy the lowest total cost was established by FUVA (US$ 5,359). It was followed 
by FOLFIRI then FOLFOX and FOLFOX, US$ 14,144 and US$ 16,553, respectively. The lowest cost for each week of life 
expectancy was established by FUVA with US$ 98.
CONCLUSIONS: Only FUFA, FOLFIRI followed by FOLFIX, FOLFIRI/bevacizumab then FOLFOX then cetuximab, 
FOLFOX/bevacizumab then irinotecan then cetuximab/irinotecan and FOLFIRI/bevacizumab then FOLFOX then cetuxi-
mab/irinotecan were under the cost effectiveness curve. In addition no treatments ICER was under the WHO`s threshold 
for Turkey, except FOLFIRI then FOLFOX compared with FUVA.
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semi synthetic inhibitor of topoisomerase, 
and oxaliplatin, a third-generation platinum 
compound, were developed as salvage the-
rapies for patients failing 5-FU [10,13,14] 
and are treatment options for first-line, se-
cond-line and sequential treatment in colo-
rectal cancer [10]. Many patients are now 
treated with sequential therapy resulting 
in prolonged overall survival to over 20 
months [10,15].
However, the cost associated with this impro-
ved survival may be very high, even in the 
United States [16]. Although there are many 
cost studies for CRC from different countries, 
there is not any cost study for Turkey where 
the government funded social security pro-
gram covers approximately 85% of the popu-
lation with Social Security Institution (SGK). 
It was reported that € 485 million was spent 
for cancer treatment by SGK in year 2009 
[17]. Although, there are studies for calcula-
ting cost of specific cancer treatments (breast 
cancer, lung cancer) in Turkey [18,19], there 
is not any published analysis for calculating 
cost of colon cancer. The aim of our study is 
to calculate the cost of colon cancer treatment 
protocols and cost per year with different 
combinations of protocols for Turkey using 
survival data calculated from a previously 
published Markov Model [16].
METHODS
Gazi University Hospital, which is the one of 
third treatment hospitals in Ankara, Turkey, 
treatment protocols for colon cancer treatment 
were used. Cost of FUFA (5 FU/LV), FOLFI-
RI, FOLFOX, bevacizumab/FUFA, bevacizu-
mab/FOLFIRI, bevacizumab/FOLFOX, irino-
tecan and irinotekan/cetixumab protocols 
were calculated (Table I and Table II).
The costs were based upon average go-
vernment reimbursement sales prices for a 70 
kg patient with body surface area of 1.7 m2. 
Only drug and hospital base applications 
costs, like physician visit, intravenous drug 
infusion, etc, were included. The cost of phar-
maceuticals and medical treatment used in the 
protocols were taken from the Social Security 
Institution’s web site [20] (http://www.sgk.
gov.tr) (Table III and Table IV). The cost of 
best supportive care was excluded.
Wong et al. developed a Markov model to 
estimate the cost effectiveness of up to three 
lines of therapy for metastatic colorectalcan-
cer [16]. In this model, patients received one, 
two or three lines of therapy. In this model 
the “base case” scenario was single agent 
5FU. We used the estimated time on each 
line of therapy to populate this model. The 
median period of each protocol administe-
red in combinations and life expectancy data 
Protocol
Pharmaceutical Administration
Day
1 2 3 4 5 14
FUFA (5FU/LV) (1 amp 
Metpamid, 1 amp Decort, 
1 amp Systal and laboratories)
5-Fluorouracil (425 mg/m2) 15 min. infusion in 250 cc SS + + + + +
Folinic acid (20 mg/m2) i.v. push + + + + +
FOLFIRI
(tropisetron 5 mg or 
ondansetron 4-8 mg, 1 amp 
Decort + 1 amp Systral and 
laboratories)
Irinotekan (180 mg/m2) 90 min. infusion in 250 cc SS +
Folinic acid (200 mg/m2) 2 hrs infusion in 250 cc SS + +
5-FU (400 mg/m2) 15 min. infusion in 250 cc SS + +
5-FU (600 mg/m2) 22 hrs infusion in 1000 cc SS + +
FOLFOX (tropisetron 5 mg or 
ondansetron 4-8 mg, 1 amp 
Dekort, 1 amp Systral)
Oxaliplatin (85 mg/m2) 2 hrs infusion in 1000 cc %5 
dextrose 
+
Folinic acid (200 mg/m2) 2 hrs infusion in 250 cc %5 
dextrose 
+ +
5-FU (400 mg/m2) 15 min. infusion in 250 cc SS + +
5-FU (600 mg/m2) 22 hrs İnfusion in 1000 cc SS + +
Bevacizumab/FUFA (1 amp 
Metpamid, 1 amp Dekort and 1 
amp Systral)
Bevacizumab (5 mg/kg) in 100 cc SS + +
5-Fluorouracil (425 mg/m2) 15 min. infusion in 250 cc SS + + + + +
Folinic acid (20 mg/m2) i.v. push + + + + +
Table I. Protocols of treatments 1
SS = saline solution
Protocol Pharmaceutical Administration
Day
1 8 15 22 29
Bevacizumab/FOLFIRI (tropisetron 
5 mg or ondansetron 4-8 mg, 1 
amp Decort + 1 amp Systral and 
laboratories)
Irinotekan (125 mg/m2) 90 min. infusion in 250 cc SS + + + +
Folinic acid (20 mg/m2) i.v. push + + + +
5-FU (500 mg/m2) 15 min. infusion in 250 cc SS + + + +
Bevacizumab (5 mg/kg) in 100 cc SS + + +
Bevacizumab/FOLFOX (tropisetron 
5 mg or ondansetron 4-8 mg, 1 amp 
Dekort, 1 amp Systral)
Bevacizumab (5 mg/kg) in 100 cc SS + +
Oxaliplatin (85 mg/m2) 2 hrs infusion in 1000 cc %5 
dextrose
+
Folinic acid (200 mg/m2) 2 hrs infusion in 250 cc %5 
dextrose 
+ +
5-FU (400 mg/m2) 15 min. infusion in 250 cc SS + +
5-FU (600 mg/m2) 22 hrs nfusion in 1000 cc SS + +
Irinotecan (tropisetron 5 mg or 
ondansetron 4-8 mg, 1 amp Dekort, 1 
amp Systral)
(350 mg/m2) 90 min infusion in 250 cc SS +
Irinotecan +Cetuximab (tropisetron 
5 mg or ondansetron 4-8 mg, 1 amp 
Dekort, 1 amp Systral)
Irinotecan (200mg) 90 min infusion in 250 cc SS + +
Cetuximab (begining 
700 mg, maintenance 
500 mg)
120 min i.v. infusion + + +
Table II. Protocols of treatments 2
Drug Package Average price (US$)
5-Fluorouracil 500 mg 2.93 (2.71-3.12)
1000 mg 5.50 (5.34-5.82)
Bevacizumab 100 mg 307.12
400 mg 1,140.55
Cetuximab 100 mg 276
500 mg 1,533.33
Folinic acid 40 mg 0.67 (0.56-0.76)
Irinotecan 40 mg 58.36
100 mg 135.66
Table III. Cost of drugs
Medical treatment Average Price (US$)
1 amp Metpamid 0.51
1 amp Decort (8 mg) 1.18
1 amp Systral 0.23
SS 100 cc 1.88
SS 250 cc 2.18
Granisetron 3 mg amp 23.70
Tropisetron 5 mg 17.39
Ondansetron 4-8 mg 3.32
Loperamid tablet 0.05
1000 cc SF 3.20
250 cc %5 dextrose 71.12
1000 cc %5 dextrose 17.39
Multiple chemotherapy infusion 34.66
Mono infusion chemotherapy 28.00
Bed for out patient 4.00
Physician visit 17.33
Laboratories 12.00
Table IV. Cost of other medical treatment
*Average of the cost of granisetron, tropisetron, ondansetron = US$ 14.80
Combination of protocols LE 
(weeks)
Total cost 
(US$)
Cost per 
LE (US$)First line Second line Third line Fourth line
FUVA Supportive care - - 54.7 5,359 98
FOLFOX Supportive care - - 70 16,553 236
FOLFIRI FOLFOX Supportive care - 84.4 14,144 167
FOLFOX and bevacizumab Irinotecan Supportive care - 95.1 63,288 665
FOLFOX Irinotecan Irinotecan/cetuximab Supportive care 104.7 113,392 1,083
FOLFIRI and bevacizumab FOLFOX Cetuximab Supportive care 113.8 135,020 1,186
FOLFOX and bevacizumab Irinotecan Cetuximab Supportive care 111.9 156,858 1,401
FOLFIRI and bevacizumab FOLFOX Cetuximab/irinotecan Supportive care 118.3 151,170 1,277
FOLFOX and bevacizumab Irinotecan Cetuximab/irinotecan Supportive care 116.7 165,052 1,414
Table V. Cost of combination of protocols
FOLFIRI = combined 5-FU, LV, and irinotecan; FOLFOX = combined 5-FU, LV, and oxaliplatin; FUVA = 5-fluouracil/leucovorin (LV);  
LE = life expectancy
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[17]. Although, there are studies for calcula-
ting cost of specific cancer treatments (breast 
cancer, lung cancer) in Turkey [18,19], there 
is not any published analysis for calculating 
cost of colon cancer. The aim of our study is 
to calculate the cost of colon cancer treatment 
protocols and cost per year with different 
combinations of protocols for Turkey using 
survival data calculated from a previously 
published Markov Model [16].
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mab/FOLFIRI, bevacizumab/FOLFOX, irino-
tecan and irinotekan/cetixumab protocols 
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The costs were based upon average go-
vernment reimbursement sales prices for a 70 
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Only drug and hospital base applications 
costs, like physician visit, intravenous drug 
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maceuticals and medical treatment used in the 
protocols were taken from the Social Security 
Institution’s web site [20] (http://www.sgk.
gov.tr) (Table III and Table IV). The cost of 
best supportive care was excluded.
Wong et al. developed a Markov model to 
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lines of therapy for metastatic colorectalcan-
cer [16]. In this model, patients received one, 
two or three lines of therapy. In this model 
the “base case” scenario was single agent 
5FU. We used the estimated time on each 
line of therapy to populate this model. The 
median period of each protocol administe-
red in combinations and life expectancy data 
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FOLFOX/bevacizumab then irinotecan then 
cetuximab and FOLFOX/bevacizumab then 
irinotecan then cetuximab/irinotecan were 
dominated. In addition, ICER of each compa-
red treatment per life expectancy year was 
higher the limits of cost effectiveness th-
reshold for Turkey which was mentioned by 
WHO [21], except FOLFIRI then FOLFOX 
compared with FUVA (Table VI).
On the other hand, if we calculate the avera-
ge weighted curve for metastatic colon can-
cer treatment`s cost compared with life ex-
pectancy, FOLFOX, FOLFOX/
bevacizumab then irinotecan, FOLFIRI 
then FOLFOX, FOLFOX/bevacizumab 
then irinotecan then cetuximab are above 
the curve. The other combinations are be-
low the curve (Figure 1).
DISCUSSION AND CONCLUSIONS
It has been estimated that there will be 
8-9,000 new colon cancer patients every year 
in Turkey, and metastatic colon cancer will be 
developed in 2-3,000 of them. Due the high 
prevalence and cost of treatment of metasta-
tic colon cancer, there may be a huge bud-
get impact to Turkish health system. Turkish 
reimbursement decisions are given by the 
commissions in Social Security Institution 
(SGK). After Ministry of Health`s approve 
the license of pharmaceuticals, all pharma-
ceuticals needs to make application to SGK 
for reimbursement. However, they need to 
show their cost-effectiveness against to avai-
lable treatment options in the market, most 
of companies perform analysis depending on 
their Phase III study in which mostly place-
bo used for comparing. However, although 
companies perform analysis for reimburse-
ment application, few analyses is published 
in journals, congress, etc. There is not any 
published pharmacoeconomic analysis for 
the colon cancer treatment in Turkey. This 
analysis is the first for the literature.
Our analysis have some limitations. Tre-
atment protocols are dependent on only one 
University Hospital. Using the treatment 
protocols from different centers may lead to 
more accurate calculations for Turkey. Life 
expectancy Markov were calculated before 
KRAS testing which was used to identify pa-
tients who would respond to cetuximab. Due 
this the life expectancy will be different now 
for the predicting patients who may respond. 
This is the major limitation for the analysis. 
It is needed to run a new Markov with KRAS 
testing. In addition, discount rate was exclu-
ded from the analysis. Because there will be a 
discount in Turkish price, exchange rate TL/
US may change in years.
Total cost 
(US$)
Life expectancy
Incremental 
cost (US$)
Incremental 
life expectancy
ICER  
(US$/LE)
FUVA (5FU/LV) 5,359 1.05 year (54.7 weeks) - - -
FOLFIRI then FOLFOX 14,144 1.62 year (84.4 weeks) 8,785 0.57 15,412
FOLFOX 16,553 1.34 year (70 years) Dominated Dominated Dominated
FOLFOX/bevacizumab then irinotecan 63,288 1.82 year (95.1 weeks) 49,144 0.2 245,720
FOLFOX then irinotecan then 
irinotecan/cetuximab
113,392 2.01 years (104.7 weeks) 50,104 0.19 263,705
FOLFIRI/bevacizumab then FOLFOX 
then cetuximab
135,020 2.18 years (113.8 weeks) 21,628 0.17 127,223
FOLFIRI/bevacizumab then FOLFOX 
then cetuximab/irinotecan
151,170 2.27 years (118.3 weeks) 16,150 0.09 179,444
FOLFOX/bevacizumab then irinotecan 
then cetuximab
156,858 2.15 years (111.9 weeks) Dominated Dominated Dominated
FOLFOX/bevacizumab then irinotecan 
then cetuximab/irinotecan
165,052 2.24 years (116.7 weeks) Dominated Dominated Dominated
Table VI. Incremental cost-effectiveness analysis of combination of treatment protocols
Figure 1. Cost-effectiveness curve of colon cancer treatments
A = FUFA; B = FOLFOX; C = FOLFIRI then FOLFOX; D = FOLFOX /bevacizumab then irinotecan; E = FOLFOX then irinotecan then irinotecan/
cetuximab; F = FOLFOX/bevacizumab then irinotecan then cetuximab; G = FOLFIRI/bevacizumab then FOLFOX then cetuximab; H = FOLFOX/
bevacizumab then irinotecan then cetuximab/irinotecan; I = FOLFIRI/bevacizumab then FOLFOX then cetuximab/irinotecan
lowed by FOLFIRI (US$ 390), irinotekan 
(US$ 619), FOLFOX (US$ 704), beva-
cizumab/FUFA (US$ 2,730), bevacizumab/
FOLFOX (US$ 4,367), bevacizumab/FOL-
FIRI (US$ 5,203) and irinotecan/cetixumab 
(US$ 11,625). Depending on the life expec-
tancy the lowest total cost was established 
by FUVA (US$ 5,359). It was followed by 
FOLFIRI then FOLFOX and FOLFOX, US$ 
14,144 and US$ 16,553, respectively. The lo-
west cost for each week of life expectancy 
was established by FUVA with US$ 98 (Ta-
ble V).
Incremental cost effectiveness ratio (ICER) 
was calculated depending on life expectan-
cies of each combination. Life expectancies 
were taken in year for ICER. FOLFOX, 
were taken from the published analysis. Cost 
of combination of protocols were calculated 
depending of these. Only cost of drugs were 
used for the calculations as in Wong`s study 
[16]. The analysis was conducted in the per-
spective of a third-party payer like the Tur-
kish Social Security Institution which covers 
the 85% of the population. The exchange rate 
was US$ 1 for TL 1.5. Incremental cost effec-
tiveness ratio (ICER) was calculated for each 
treatment. Life expectancy was calculated to 
years from weeks for ICER. The threshold 
for ICER was taken from WHO [21].
RESULTS
The lowest cost for one cycle/month was 
established by FUFA (US$ 342). It was fol-
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A USA study [22] evaluated the cost per 6 
months of different treatment regimens: FU/
LV daily for 5 days, monthly (US$ 96), infu-
sional FU/LV every 2 weeks (US$ 352), ca-
pecitabine for 14 days, every 3 weeks (US$ 
11,648), irinotecan every 3 weeks (US$ 
30,100), irinotecan weekly for 4 weeks, eve-
ry 6 weeks (US$ 21,500), FOLFIRI every 
2 weeks (US$ 23,572), FOLFOX every 2 
weeks (US$ 29,989), bevacizumab (alone) 
every 2 weeks (US$ 23,897), cetuximab mo-
notherapy weekly (US$ 52,131), and pani-
tumumab (US$ 44,720). findings are similar 
to our findings. New drugs are serving more 
costly treatment option with higher survival 
rates than the older drugs.
Only FUFA, FOLFIRI then FOLFIX, FOL-
FIRI/bevacizumab then FOLFOX then cetu-
ximab, FOLFOX/bevacizumab then irinote-
can then cetuximab/irinotecan and FOLFIRI/
bevacizumab then FOLFOX then cetuximab/
irinotecan were under the cost-effectiveness 
curve.
There is no set definition of cost-effective 
and this may vary from country to country. 
The World Health Organization noted that if 
the ICER is lower than gross domestic pro-
duct per capita (GDPC) or between 1-3 x 
GDPC or higher than 3 x GDPC, it is very 
cost-effective, cost-effective or not cost-ef-
fective, respectively [21]. In this report the 
cost-effectiveness threshold is US$ 9,972 for 
Turkey region, which is consistent with the 
GDP of US$ 10,000 per year. The cost-effec-
tiveness can be considered from US$ 9,972 
to US$ 29,915 for each life year gained or 
quality adjusted life year.
The other combinations of protocols were 
above the cost-effectiveness curve depen-
ding on life expectancy. In addition no tre-
atments ICER was under the WHO’s th-
reshold for Turkey, except FOLFIRI then 
FOLFOX compared with FUVA. It is pos-
sible that if a formal cost-utility analysis 
was performed in Turkey, it would be very 
difficult to justify the current prices of phar-
maceuticals and almost all high priced phar-
maceuticals would not demonstrate enou-
gh value to be reimbursed like oncology, 
orphan, etc. On the other hand, cost-utility 
analysis would be of more use to demonstra-
te the value of oncology medicines. Even 
then, oncology medicines are being reim-
bursed in Turkey whether they can or cannot 
demonstrate value using cost-effectiveness 
analysis because it would not be acceptable 
if there were news in media such that some 
oncology patients died due to the fact that 
government did not reimburse oncology 
medicines. Because there is also a traditio-
nal way of thinking in Turkey, such as when 
FOLFOX/bevacizumab then irinotecan then 
cetuximab and FOLFOX/bevacizumab then 
irinotecan then cetuximab/irinotecan were 
dominated. In addition, ICER of each compa-
red treatment per life expectancy year was 
higher the limits of cost effectiveness th-
reshold for Turkey which was mentioned by 
WHO [21], except FOLFIRI then FOLFOX 
compared with FUVA (Table VI).
On the other hand, if we calculate the avera-
ge weighted curve for metastatic colon can-
cer treatment`s cost compared with life ex-
pectancy, FOLFOX, FOLFOX/
bevacizumab then irinotecan, FOLFIRI 
then FOLFOX, FOLFOX/bevacizumab 
then irinotecan then cetuximab are above 
the curve. The other combinations are be-
low the curve (Figure 1).
DISCUSSION AND CONCLUSIONS
It has been estimated that there will be 
8-9,000 new colon cancer patients every year 
in Turkey, and metastatic colon cancer will be 
developed in 2-3,000 of them. Due the high 
prevalence and cost of treatment of metasta-
tic colon cancer, there may be a huge bud-
get impact to Turkish health system. Turkish 
reimbursement decisions are given by the 
commissions in Social Security Institution 
(SGK). After Ministry of Health`s approve 
the license of pharmaceuticals, all pharma-
ceuticals needs to make application to SGK 
for reimbursement. However, they need to 
show their cost-effectiveness against to avai-
lable treatment options in the market, most 
of companies perform analysis depending on 
their Phase III study in which mostly place-
bo used for comparing. However, although 
companies perform analysis for reimburse-
ment application, few analyses is published 
in journals, congress, etc. There is not any 
published pharmacoeconomic analysis for 
the colon cancer treatment in Turkey. This 
analysis is the first for the literature.
Our analysis have some limitations. Tre-
atment protocols are dependent on only one 
University Hospital. Using the treatment 
protocols from different centers may lead to 
more accurate calculations for Turkey. Life 
expectancy Markov were calculated before 
KRAS testing which was used to identify pa-
tients who would respond to cetuximab. Due 
this the life expectancy will be different now 
for the predicting patients who may respond. 
This is the major limitation for the analysis. 
It is needed to run a new Markov with KRAS 
testing. In addition, discount rate was exclu-
ded from the analysis. Because there will be a 
discount in Turkish price, exchange rate TL/
US may change in years.
Total cost 
(US$)
Life expectancy
Incremental 
cost (US$)
Incremental 
life expectancy
ICER  
(US$/LE)
FUVA (5FU/LV) 5,359 1.05 year (54.7 weeks) - - -
FOLFIRI then FOLFOX 14,144 1.62 year (84.4 weeks) 8,785 0.57 15,412
FOLFOX 16,553 1.34 year (70 years) Dominated Dominated Dominated
FOLFOX/bevacizumab then irinotecan 63,288 1.82 year (95.1 weeks) 49,144 0.2 245,720
FOLFOX then irinotecan then 
irinotecan/cetuximab
113,392 2.01 years (104.7 weeks) 50,104 0.19 263,705
FOLFIRI/bevacizumab then FOLFOX 
then cetuximab
135,020 2.18 years (113.8 weeks) 21,628 0.17 127,223
FOLFIRI/bevacizumab then FOLFOX 
then cetuximab/irinotecan
151,170 2.27 years (118.3 weeks) 16,150 0.09 179,444
FOLFOX/bevacizumab then irinotecan 
then cetuximab
156,858 2.15 years (111.9 weeks) Dominated Dominated Dominated
FOLFOX/bevacizumab then irinotecan 
then cetuximab/irinotecan
165,052 2.24 years (116.7 weeks) Dominated Dominated Dominated
Table VI. Incremental cost-effectiveness analysis of combination of treatment protocols
Figure 1. Cost-effectiveness curve of colon cancer treatments
A = FUFA; B = FOLFOX; C = FOLFIRI then FOLFOX; D = FOLFOX /bevacizumab then irinotecan; E = FOLFOX then irinotecan then irinotecan/
cetuximab; F = FOLFOX/bevacizumab then irinotecan then cetuximab; G = FOLFIRI/bevacizumab then FOLFOX then cetuximab; H = FOLFOX/
bevacizumab then irinotecan then cetuximab/irinotecan; I = FOLFIRI/bevacizumab then FOLFOX then cetuximab/irinotecan
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is unique for literature. Further analysis is 
needed to be performed depending on new 
clinical outcomes and cost data.
it is a health issue, it is not well accepted 
by public to talk about costs and money, as 
maintaining health should be more impor-
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treatments are covered by reimbursement 
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said that it is hard to change the reimburse-
ment decision about this disease due to the 
low survival rate of colon cancer and social 
25Farmeconomia. Health economics and therapeutic pathways 2013; 14(1) © SEEd All rights reserved
G. Kockaya, M. Polat, A. I. Wertheimer, A. Özet, S. Malhan, İ. M. Vural, A. Akbulat, G. Artıran, H. Gürsöz, S. Kerman
18. Uslu R, Kapkac M, Karaca B, et al. Screening for metastasis in primary breast cancer patients having four or more 
axillary lymph node involvement: is it really necessary? J BUON 2010; 15: 561-7
19. Cakir Edis E, Karlikaya C. The cost of lung cancer in Turkey. Tuberk Toraks 2007; 55: 51-8
20. Republic of Turkey. Social Security Institution. Available via URL: http://www.sgk.gov.tr
21. WHO. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Available via URL: http://www.who.int/
choice/costs/CER_thresholds/en/index.html
22. Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol 2007; 25: 180-6
23. National Service Center for Environmental Publications. Cost of illness. Enviromental Protection Agency, 2007. 
Available via URL: http://www.epa.gov/opptintr/coi/pubs/II_7.pdf
